Healthcare and life sciences

Bär & Karrer Ltd.

Client Satisfaction

The market-leading team at Bär & Karrer Ltd. advises its lucrative client base of on the full gamut of matters, including the marketing and advertising of drugs and pricing proceedings. Jointly heading the practice in Zurich, Markus Schott primarily focuses on administrative proceedings, including government supervision and public procurement mandates; Markus Wang leads on the intellectual property (IP) side, acting for pharma and biotech clients in Swissmedic proceedings; and Philippe Seiler maintains a private equity and M&A focused practice, handling a variety of transactions and regulatory matters involving medical device and drug distribution. Basel based practice co-head Claudia Götz Staehelin is an expert in investigations, disputes, and regulatory issues, representing numerous global pharma giants, while co-head Oliver Brupbacher is noted for his ‘exceptional’ sector knowledge, and his expertise in crisis management issues and information governance. Jannick Koller left the practice in December 2022.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘The team has a deep knowledge of pharmaceutical business. They do understand the business aspects and not just the legal issues. Their responsiveness is really remarkable. ’
‘Markus Schott has a great understanding of the legal issues of our company but also he understands in-depth our business needs. this is a combination that leads to excellent cooperation.’
‘The team covers a full range of legal issues and expertise. Very strong life science understanding.’
‘Oliver Brupbacher has exceptional knowledge of the life science sector and an extremely pragmatic and result-driven approach. He is fast, available, and partners on cases.’
‘B&K is a full service law firm with depth in many areas of relevance.’
‘The team at Bär & Karrer Ltd. are highly focused on client service and attention to detail, which when combined with their strong depth of knowledge in their respective subject matter areas, sets them apart from their competitors. In particular, the quality of service and work product provided by Oliver Brupbacher is exceptional. ’

Key clients

Novartis

Work highlights

Advised Firmenich on its merger with DSM, which was announced on the 31 May 2022. The new parent company will be located in Switzerland and listed on Euronext Amsterdam.
Advises Moderna on various legal matters in connection with its business in Switzerland and abroad, including legal and regulatory advice related to the establishment of its supply chain for its Covid-19 Vaccine, Swiss launch preparations, trade and commercial matters, as well as health care compliance and regulatory aspects and data privacy.
Advising Novartis in the planned spin-off of Sandoz.